ABBV vs. MA: AbbVie vs. Mastercard Stock Comparison

November 11, 2026

How do AbbVie (ABBV) and Mastercard (MA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Mastercard (MA) belongs to Financials (Financial Services) — their GICS classifications point to very different parts of the market.

Company profile comparison for AbbVie (ABBV) and Mastercard (MA)
Profile Item	ABBV	MA
Name	AbbVie Inc.	Mastercard Inc. Class A Common Stock
Country/Region	United States	United States
GICS Sector	Health Care	Financials
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Financial Services
GICS Industry	Biotechnology	Financial Services
GICS Sub-Industry	Biotechnology	Transaction & Payment Processing Services
Market Capitalization	514.92 billion USD	568.62 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	January 2, 2013	May 25, 2006
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ABBV

GSPC

AbbVie (ABBV) vs. Mastercard (MA), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AbbVie (ABBV) and Mastercard (MA). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AbbVie (ABBV) and Mastercard (MA). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Mastercard (MA)
Metric	ABBV	MA
Total Return (1Y)	37.33%	20.00%
Total Return (3Y, Annualized)	32.74%	19.98%
Total Return (5Y, Annualized)	24.73%	14.49%

Risk Profile

Drawdown History

ABBV

GSPC

AbbVie (ABBV) vs. Mastercard (MA), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AbbVie (ABBV) and Mastercard (MA). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and Mastercard (MA)
Metric	ABBV	MA
Volatility (1Y, Annualized)	25.65%	23.57%
Beta (5Y)	0.21	0.76
Max Drawdown (5Y)	-21.92%	-28.25%
Avg. Volume (3M)	4.76M	2.98M

Risk-Adjusted Performance

Risk-Return Positioning

ABBV and MA are plotted by 1-year volatility (risk) and 1-year return. Each dashed Capital Allocation Line uses that stock's own industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Mastercard (MA)
Metric	ABBV	MA
Sharpe Ratio (1Y)	1.29	0.67
Sortino Ratio (1Y)	2.02	1.00

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Mastercard (MA) earns 231.37% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ABBV: --

MA

Financial Services industry group

231.37%

MA: 231.37%
Max: 44.78%
Q3: 21.85%
Median: 12.91%
Q1: 4.48%
Min: -18.71%

AbbVie (ABBV) vs. Mastercard (MA): ABBV does not report ROE, so it has no value marker; MA is benchmarked against the Financial Services industry group.

Net Margin (TTM)

For every dollar of sales, both AbbVie (ABBV) at 15.67% and Mastercard (MA) at 46.73% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max: 18.05%
ABBV: 15.67%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MA

Financial Services industry group

46.73%

Max: 62.84%
MA: 46.73%
Q3: 28.05%
Median: 15.36%
Q1: 4.82%
Min: -28.52%

AbbVie (ABBV) vs. Mastercard (MA): A comparison of their net margin against their respective Pharmaceuticals, Biotechnology & Life Sciences and Financial Services industry group benchmarks.

Operating Margin (TTM)

Both AbbVie (ABBV) at 39.59% and Mastercard (MA) at 60.53% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max: 83.12%
ABBV: 39.59%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MA

Financial Services industry group

60.53%

Max: 107.33%
MA: 60.53%
Q3: 55.90%
Median: 30.09%
Q1: 14.60%
Min: -44.34%

AbbVie (ABBV) vs. Mastercard (MA): A comparison of their operating margin against their respective Pharmaceuticals, Biotechnology & Life Sciences and Financial Services industry group benchmarks.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Mastercard (MA)
Metric	ABBV	MA
ROE (TTM)	--	231.37%
ROA (TTM)	10.74%	24.45%
Net Margin (TTM)	15.67%	46.73%
Operating Margin (TTM)	39.59%	60.53%
Gross Margin (TTM)	73.72%	--

Growth

Revenue Growth

Both AbbVie (ABBV) at 8.57% and Mastercard (MA) at 16.42% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

AbbVie (ABBV) vs. Mastercard (MA): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both AbbVie (ABBV) at -0.84% and Mastercard (MA) at 18.93% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

AbbVie (ABBV) vs. Mastercard (MA): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and Mastercard (MA)
Metric	ABBV	MA
Revenue Growth (YoY)	8.57%	16.42%
Revenue Growth (3Y CAGR)	1.75%	13.82%
EPS Growth (YoY)	-0.84%	18.93%
EPS Growth (3Y CAGR)	-29.03%	17.36%

Financial Strength

Current Ratio (MRQ)

AbbVie (ABBV) shows current ratio of 0.87; Mastercard (MA) doesn’t get one — Financial Services balance sheets aren’t split into current and non-current buckets, so short-term liquidity there is judged through regulatory measures instead.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ABBV: 0.87
Min: 0.10

MA

Financial Services industry group

MA: --
Max: --
Q3: --
Median: --
Q1: --
Min: --

AbbVie (ABBV) vs. Mastercard (MA): MA’s current ratio is not assessed under the Financial Services industry convention, so the chart shows available visual context for ABBV only.

Debt / Equity (MRQ)

AbbVie (ABBV) has no debt-to-equity ratio value reported for this period; for Mastercard (MA), debt-to-equity ratio isn’t a meaningful figure under the Financial Services industry convention — no peer-based comparison can be drawn.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
ABBV: --

MA

Financial Services industry group

MA: --
Max: --
Q3: --
Median: --
Q1: --
Min: --

AbbVie (ABBV) vs. Mastercard (MA): ABBV does not report debt-to-equity ratio; MA’s debt-to-equity ratio is not assessed under the Financial Services industry convention.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Mastercard (MA)
Metric	ABBV	MA
Current Ratio (MRQ)	0.87	--
Debt / Equity (MRQ)	--	--
Net Debt / EBITDA	2.21	--

Dividends

Dividend Yield (TTM)

Mastercard (MA) at 0.53% pays an industry-typical yield; AbbVie (ABBV) at 2.40% is above its entire peer range — the higher number, but one that calls for a look at payout sustainability before treating it as an advantage.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV: 2.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MA

Financial Services industry group

0.53%

Max: 9.77%
Q3: 3.92%
Median: 1.09%
MA: 0.53%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Mastercard (MA): A comparison of their dividend yield against their respective Pharmaceuticals, Biotechnology & Life Sciences and Financial Services industry group benchmarks.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Mastercard (MA) reports 17.63%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV: 117.35%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MA

Financial Services industry group

17.63%

Max: 241.07%
Q3: 97.36%
Median: 25.77%
MA: 17.63%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Mastercard (MA): A comparison of their payout ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Financial Services industry group benchmarks.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Mastercard (MA)
Metric	ABBV	MA
Dividend Yield (TTM)	2.40%	0.53%
Dividend Payout Ratio (TTM)	117.35%	17.63%

Valuation

P/E Ratio (TTM)

Both AbbVie (ABBV) at 50.05 and Mastercard (MA) at 34.15 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max: 85.34
ABBV: 50.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

MA

Financial Services industry group

34.15

Max: 45.85
MA: 34.15
Q3: 24.64
Median: 15.37
Q1: 9.68
Min: 0.16

AbbVie (ABBV) vs. Mastercard (MA): A comparison of their P/E ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Financial Services industry group benchmarks.

P/S Ratio (TTM)

AbbVie (ABBV) at 7.80 prices around its industry’s typical P/S ratio, while Mastercard (MA) at 15.67 clears its benchmark range — MA looks notably rich on sales.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max: 58.18
Q3: 25.77
ABBV: 7.80
Median: 7.30
Q1: 3.01
Min: 0.01

MA

Financial Services industry group

15.67

MA: 15.67
Max: 9.23
Q3: 4.57
Median: 2.72
Q1: 1.28
Min: -0.55

AbbVie (ABBV) vs. Mastercard (MA): A comparison of their P/S ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Financial Services industry group benchmarks.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Mastercard (MA) reports 84.30, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
ABBV: -112.34

MA

Financial Services industry group

84.30

MA: 84.30
Max: 7.79
Q3: 3.63
Median: 1.57
Q1: 0.81
Min: -0.39

AbbVie (ABBV) vs. Mastercard (MA): A comparison of their P/B ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Financial Services industry group benchmarks.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Mastercard (MA)
Metric	ABBV	MA
P/E Ratio (TTM)	50.05	34.15
P/S Ratio (TTM)	7.80	15.67
P/B Ratio (MRQ)	-112.34	84.30
Free Cash Flow Yield (TTM)	3.44%	--